Anti-inflammatory use during surgery could improve cancer outcomes
Share

IMAGE: Professor Paul Redmond, RCSI Council member and Chair of Surgery at Cork University Hospital (CUH) who led the SURGUVANT clinical trial with Mr Peter O’Leary, CUH Department of Surgery view more 

view more 

Monday, 3 September 2018: The world’s first clinical trial (SURGUVANT) evaluating anti-inflammatory use at the time of surgery in colon cancer patients to improve their cancer outcome has been published in scientific journal, BMC Cancer.

The research successfully tested an anti-inflammatory agent with anti-cancer properties known as ‘Taurolidine’ in the SURGUVANT trial which was funded by a grant from Geistlich Pharma AG, Wolhusen, Switzerland. The research was undertaken by researchers at RCSI in Dublin in collaboration with the Cork University Hospital group, University College Cork, Mercy University Hospital and the Bon Secours Hospital, Cork led by Professor Paul Redmond, RCSI Council member and Chair of Surgery at Cork University Hospital and Mr Peter O’Leary, CUH Department of Surgery.

The Surguvant trial examined a link between surgical inflammation and the recurrence of cancer. The trial randomised patients undergoing surgery for colon cancer to either a placebo or 2% Taurolidine solution. The trial reported that important components of the inflammatory response to surgery that have been shown to propagate tumour

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD